Premium
Use of infliximab‐daclizumab combination for the treatment of acute and chronic graft‐versus‐host disease of the liver and gut
Author(s) -
Rodriguez Vilmarie,
Anderson Peter M.,
Trotz Barbara A.,
Arndt Carola A.S.,
Allen Julia A.,
Khan Shakila P.
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20648
Subject(s) - daclizumab , medicine , infliximab , tacrolimus , prednisone , graft versus host disease , gastroenterology , liver transplantation , transplantation , disease
Infliximab‐daclizumab was used to treat acute and chronic liver and gut graft‐versus‐host disease (GVHD) in two children after standard immunosuppressive therapy failed. Infliximab (10 mg/kg weekly, 4 doses) and daclizumab (1 mg/kg, days 1, 4, 8, 15, and 22) were given over 1 month. In case 1, grade 2 chronic GVHD of the liver developed 1 year after transplantation and failed to improve with tacrolimus, mycophenolate mofetil, and prednisone. In case 2, corticosteroid‐unresponsive grade 3 acute liver and gut GVHD developed on day +37. In both patients, GVHD responded to the infliximab‐daclizumab regimen without toxicity and immunosuppressive therapy was discontinued. Pediatr Blood Cancer 2007;49:212–215. © 2005 Wiley‐Liss, Inc.